retatrutide fda approval status eli lilly Shruti Sinha on X: "🧬 The Drug Trial reports two more successful Phase 3 results and moves closer to review. Read more: https://t.co/TIYeT2tZyv #EliLillyRetatrutideDrugTrial #ClinicalTrials #FDA #Healthcare #ObesityResearch" Eli Lilly's retatrutide hits Phase

Regardless of cause, sustainability of outcomes remains unclear because adherence to treatment, as with many other drugs, may be an issue

Biomedicine & Pharmacotherapy, 134 , 111129

This head injury was more concerning than in the past and the patient had suffered a concussion

Choosing Between Semaglutide and Tirzepatide for Microdosing From a pharmacology standpoint, semaglutide is a pure GLP-1 receptor agonist , while tirzepatide is a dual GIP/GLP-1 agonist that activates both GIP and GLP-1 receptors.[2,4] That dual mechanism likely contributes to tirzepatides strong weight-loss results at full doses compared with semaglutide in head-to-head and indirect comparisons.[2,7] In the context of microdosing: Some clinicians and patients feel that microdosing tirzepatide provides robust appetite control even at relatively low doses, though this is based largely on real-world experience rather than large trials